Coccidioidomycosis during pregnancy: a review and recommendations for management.

Abstract

Pregnancy is an established risk factor for the development of severe and disseminated coccidioidomycosis, particularly when infection is acquired during the later stages of gestation. Although recent studies suggest that the incidence of symptomatic coccidioidomycosis during pregnancy is decreasing and that outcome has improved, management is complicated by the observations that azole antifungal agents can be teratogenic when given to some women, particularly at high doses, early in pregnancy. This article summarizes the data on these issues and offers guidance on the management of coccidioidomycosis during pregnancy.

• Authors: Robert S Bercovitch, Antonino Catanzaro, Brian S Schwartz, Demosthenes Pappagianis, D Heather Watts, Neil M Ampel
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 53 Issue 4 Pg. 363-8 (Aug 2011) ISSN: 1537-6591 [Electronic] United States
• PMID: 21810749 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Review)

Chemical References

• Antifungal Agents

Topics

• Animals
• Antifungal Agents (adverse effects, therapeutic use)
• Coccidioidomycosis (drug therapy)
• Female
• Humans
• Infant, Newborn
• Pregnancy
• Pregnancy Complications, Infectious (drug therapy, microbiology)